Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nobuko Hijiya

Showing results (61-70 of 85) with videos related to

Pageof 9
Sort By:
Blood Advances|July 26, 2021
A phase 2 study of nilotinib in pediatric patients with CML: long-term update on growth retardation and safetyNobuko Hijiya, Alexey Maschan, Carmelo Rizzari, et al.
Blood Advances|September 22, 2023
The long-term efficacy and safety of nilotinib in pediatric patients with CML: a 5-year update of the DIALOG studyNobuko Hijiya, Alexey Maschan, Carmelo Rizzari, et al.
Pediatric Blood & Cancer|April 1, 2018
Phase I trial of the mTOR inhibitor everolimus in combination with multi-agent chemotherapy in relapsed childhood acute lymphoblastic leukemiaAndrew E Place, Yana Pikman, Kristen E Stevenson, et al.
Blood|September 13, 2019
Phase 2 study of nilotinib in pediatric patients with Philadelphia chromosome-positive chronic myeloid leukemiaNobuko Hijiya, Alexey Maschan, Carmelo Rizzari, et al.
Cancers|February 10, 2024
Nivolumab Plus 5-Azacitidine in Pediatric Relapsed/Refractory Acute Myeloid Leukemia (AML): Phase I/II Trial Results from the Therapeutic Advances in Childhood Leukemia and Lymphoma (TACL) ConsortiumAnupam Verma, Yueh-Yun Chi, Jemily Malvar, et al.
Blood|July 28, 2021
High-dose AraC is essential for the treatment of ML-DS independent of postinduction MRD: results of the COG AAML1531 trialJohann Hitzler, Todd Alonzo, Robert Gerbing, et al.
Haematologica|October 20, 2022
Three-year results from phase I of ZUMA-4: KTE-X19 in pediatric relapsed/refractory acute lymphoblastic leukemiaAlan S Wayne, Van Huynh, Nobuko Hijiya, et al.
Leukemia|January 27, 2023
Management of children and adolescents with chronic myeloid leukemia in blast phase: International pediatric CML expert panel recommendationsStephanie Sembill, Maria Ampatzidou, Sonali Chaudhury, et al.
Pediatric Hematology and Oncology|April 28, 2020
A phase I study of panobinostat in children with relapsed and refractory hematologic malignanciesJohn Goldberg, Maria Luisa Sulis, Julia Bender, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 3, 2018
Dasatinib in Pediatric Patients With Chronic Myeloid Leukemia in Chronic Phase: Results From a Phase II TrialLia Gore, Pamela R Kearns, Maria Lucia de Martino, et al.
Pageof 9

Showing results (61-70 of 85) with videos related to

Sort By:
Pageof 9
Blood Advances|July 26, 2021
A phase 2 study of nilotinib in pediatric patients with CML: long-term update on growth retardation and safetyNobuko Hijiya, Alexey Maschan, Carmelo Rizzari, et al.
Blood Advances|September 22, 2023
The long-term efficacy and safety of nilotinib in pediatric patients with CML: a 5-year update of the DIALOG studyNobuko Hijiya, Alexey Maschan, Carmelo Rizzari, et al.
Pediatric Blood & Cancer|April 1, 2018
Phase I trial of the mTOR inhibitor everolimus in combination with multi-agent chemotherapy in relapsed childhood acute lymphoblastic leukemiaAndrew E Place, Yana Pikman, Kristen E Stevenson, et al.
Blood|September 13, 2019
Phase 2 study of nilotinib in pediatric patients with Philadelphia chromosome-positive chronic myeloid leukemiaNobuko Hijiya, Alexey Maschan, Carmelo Rizzari, et al.
Cancers|February 10, 2024
Nivolumab Plus 5-Azacitidine in Pediatric Relapsed/Refractory Acute Myeloid Leukemia (AML): Phase I/II Trial Results from the Therapeutic Advances in Childhood Leukemia and Lymphoma (TACL) ConsortiumAnupam Verma, Yueh-Yun Chi, Jemily Malvar, et al.
Blood|July 28, 2021
High-dose AraC is essential for the treatment of ML-DS independent of postinduction MRD: results of the COG AAML1531 trialJohann Hitzler, Todd Alonzo, Robert Gerbing, et al.
Haematologica|October 20, 2022
Three-year results from phase I of ZUMA-4: KTE-X19 in pediatric relapsed/refractory acute lymphoblastic leukemiaAlan S Wayne, Van Huynh, Nobuko Hijiya, et al.
Leukemia|January 27, 2023
Management of children and adolescents with chronic myeloid leukemia in blast phase: International pediatric CML expert panel recommendationsStephanie Sembill, Maria Ampatzidou, Sonali Chaudhury, et al.
Pediatric Hematology and Oncology|April 28, 2020
A phase I study of panobinostat in children with relapsed and refractory hematologic malignanciesJohn Goldberg, Maria Luisa Sulis, Julia Bender, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 3, 2018
Dasatinib in Pediatric Patients With Chronic Myeloid Leukemia in Chronic Phase: Results From a Phase II TrialLia Gore, Pamela R Kearns, Maria Lucia de Martino, et al.
Pageof 9